See ratings and reviews when you sign up for an account.

Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine

This study is currently Recruiting

July 2011 By Neurology Group of Bergen County, P.A.

First Recieved on June 15, 2010

Last Updated on July 19, 2011

Sponsor: Neurology Group of Bergen County, P.A.
Collaborators: Shire Pharmaceutical Development
Information provided by: Neurology Group of Bergen County, P.A.
Identifier: NCT01146002


This study is investigating the effect of sustained-release guanfacine (Intuniv) on language-based learning skills in children age 6-12 who are diagnosed with attention deficit hyperactivity disorder (ADHD).

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Ages Eligible for Study:6 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:Accepts Healthy Volunteers

Inclusion Criteria: Diagnosis of ADHD-inattentive or combined type. Exclusion Criteria: - Intelligence (IQ) below 85 as determined by formal testing. - Identified or suspected genetic syndromes. - Autism or other pervasive developmental disorders. - Psychiatric disorders other than ADHD and oppositional defiant disorder. - Heart, liver or renal disease. - Cancer. - Epilepsy or non-febrile seizure history. - Cardiac arrhythmia, bradycardia, or syncope. - Any other condition considered to be potentially exacerbated or endangered by treatment with an alpha-2 agonist drug.



  • Neurology Group of Bergen County

    Ridgewood, New Jersey 07450 United States

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.